BCG vaccine leads to long-term blood sugar improvement in type 1 diabetes
22 June 2018 | By European Pharmaceutical Review
A study has found a novel mechanism underlying stable, durable blood sugar control...
List view / Grid view
Type 1 Diabetes
EMA accepts Marketing Authorisation Variation for Forxiga in adults with type-1 diabetes
6 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
First European filing acceptance of a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor in type-1 diabetes...
Drug-delivering capsules could sustain transplanted insulin-producing cells
14 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A drug-carrying microsphere within a cell-bearing microcapsule could be the key to transplanting insulin-secreting pig pancreas cells into human patients...
Removable implant may control type 1 diabetes
3 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have devised a method for implanting islet cells into a patient that may control the management of type 1 diabetes...
FDA approves Admelog, the first follow-on insulin product to treat diabetes
12 December 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
The FDA has approved Admelog, a short-acting insulin indicated to improve control in blood sugar levels in diabetes...
Type 2 diabetes drug provides significant benefits to type 1 diabetic patients
14 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
A study has found that a majority of patients with Type 1 diabetes who were treated with dapagliflozin, a Type 2 diabetes medicine, had a significant decline in their blood sugar levels...
2017 pipelines: Analysing future trends in the $12billion diabetes market
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
Boehringer Ingelheim and Lilly to feature 30 presentations on type 1 and type 2 diabetes
5 June 2012 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are pleased to announce that less than two years after forming a strategic alliance aimed at bringing new treatments to patients with diabetes, the companies will present 30 abstracts across three compounds and three classes of medicine at the 72nd American…
Follow: